These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17407159)

  • 21. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
    Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
    Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
    Swellam M; Arab LR; Bushnak HA
    IUBMB Life; 2007 Jun; 59(6):394-401. PubMed ID: 17613170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
    Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
    Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
    Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
    Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
    Bewick M; Conlon M; Gerard S; Lee H; Parissenti AM; Zhang L; Glück S; Lafrenie RM
    Bone Marrow Transplant; 2001 Apr; 27(8):847-53. PubMed ID: 11477443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Clin Cancer Res; 2005 May; 11(9):3257-64. PubMed ID: 15867221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
    Klintman M; Ørnbjerg Würtz S; Christensen IJ; Braemer Hertel P; Fernö M; Malmberg M; Mouridsen H; Cold F; Schrohl AS; Foekens JA; Malmström P; Brünner N
    Breast Cancer Res Treat; 2010 Jun; 121(2):365-71. PubMed ID: 19653096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
    Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
    Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
    Larsen MB; Stephens RW; Brünner N; Nielsen HJ; Engelholm LH; Christensen IJ; Stetler-Stevenson WG; Høyer-Hansen G
    Scand J Immunol; 2005 May; 61(5):449-60. PubMed ID: 15882437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
    Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma.
    Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Breast Cancer Res Treat; 2005 Jan; 89(1):29-34. PubMed ID: 15666194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer.
    Hammer JH; Basse L; Svendsen MN; Werther K; Brünner N; Christensen IJ; Nielson HJ
    Colorectal Dis; 2006 Mar; 8(3):168-72. PubMed ID: 16466554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
    Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
    Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
    Singhal H; Bautista DS; Tonkin KS; O'Malley FP; Tuck AB; Chambers AF; Harris JF
    Clin Cancer Res; 1997 Apr; 3(4):605-11. PubMed ID: 9815727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.